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Abstract
Objectives To develop a risk prediction model to preoperatively
discriminate between benign, borderline, stage I invasive, stage II-IV
invasive, and secondary metastatic ovarian tumours.
Design Observational diagnostic study using prospectively collected
clinical and ultrasound data.
Setting 24 ultrasound centres in 10 countries.
ParticipantsWomen with an ovarian (including para-ovarian and tubal)
mass and who underwent a standardised ultrasound examination before
surgery. The model was developed on 3506 patients recruited between
1999 and 2007, temporally validated on 2403 patients recruited between
2009 and 2012, and then updated on all 5909 patients.
Main outcomemeasuresHistological classification and surgical staging
of the mass.
Results The Assessment of Different NEoplasias in the adneXa (ADNEX)
model contains three clinical and six ultrasound predictors: age, serum
CA-125 level, type of centre (oncology centres v other hospitals),
maximum diameter of lesion, proportion of solid tissue, more than 10
cyst locules, number of papillary projections, acoustic shadows, and
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ascites. The area under the receiver operating characteristic curve (AUC)
for the classic discrimination between benign and malignant tumours
was 0.94 (0.93 to 0.95) on temporal validation. The AUC was 0.85 for
benign versus borderline, 0.92 for benign versus stage I cancer, 0.99
for benign versus stage II-IV cancer, and 0.95 for benign versus
secondarymetastatic. AUCs betweenmalignant subtypes varied between
0.71 and 0.95, with an AUC of 0.75 for borderline versus stage I cancer
and 0.82 for stage II-IV versus secondary metastatic. Calibration curves
showed that the estimated risks were accurate.
Conclusions The ADNEX model discriminates well between benign
andmalignant tumours and offers fair to excellent discrimination between
four types of ovarian malignancy. The use of ADNEX has the potential
to improve triage and management decisions and so reduce morbidity
and mortality associated with adnexal pathology.
Introduction
Ovarian cancer is the most aggressive gynaecological
malignancy. The five year survival rate of patients is around
40% and the disease accounts for approximately half of all
deaths related to gynaecological cancer.1 2 The most important
factor for survival is stage at diagnosis.3 Therefore attempts
have been made to develop a screening method, which by
detecting ovarian cancer at an early stage has the potential to
decrease deaths from ovarian cancer. No such screening method
is currently available.4 5 However, we are still awaiting the
results of the United Kingdom Collaborative Trial on Ovarian
Cancer Screening.6
An important factor that influences prognosis other than stage
at diagnosis is referral to a gynaecology oncology centre for
further diagnosis or staging, debulking surgery, and evaluation
by an interdisciplinary tumour board.7-10 Although such
centralised care is recommended because it results in improved
prognosis, a large proportion of women with ovarian cancer
remain treated by general surgeons,11-13 possibly because the
true nature of the disease is unknown before surgery. Optimal
treatment of ovarian malignancies depends on the type of
tumour. Treatment of borderline tumours can be less aggressive
than treatment of invasive tumours, especially if the preservation
of fertility is important.14 In selected cases, stage I ovarian cancer
may be managed more conservatively than late stage disease,
whereas for cancers metastasised to the ovary management
depends on the origin of the primary tumour.15 An accurate
specific diagnosis of adnexal tumours before surgery will almost
certainly improve the triage of patients and so increase the
likelihood that patients will receive appropriate treatment.
Recently, the International Ovarian Tumour Analysis (IOTA)
group showed that polytomous risk prediction for the diagnosis
of ovarian cancer is feasible.16 Mathematical models were
developed to predict four tumour categories: benign, borderline,
primary ovarian cancer, and secondary metastatic cancer. This
work focused on comparing mathematical algorithms. From a
clinical point of view it was preliminary for several reasons.
Firstly, the model was built using information from only 754
patients with 40 borderline, 121 primary invasive, and 30
secondary metastatic cancers. Secondly, despite that more than
30 clinical and ultrasound candidate predictors were statistically
evaluated, the tumourmarker serumCA-125was not considered.
Althoughwe have shown that serumCA-125may not be needed
inmodels with a binary outcome (benign vmalignant),17CA-125
is likely to be important for distinguishing between different
types of malignant tumour.18 Thirdly, the models did not
distinguish between stage I and stage II-IV primary cancer,
which is clinically important.19
We developed a polytomous risk prediction model that can
reliably distinguish between benign, borderline, stage I invasive,
stage II-IV invasive, and secondary metastatic adnexal tumours.
Methods
Design and setting
We carried out an international multicentre prospective cohort
study of women with at least one adnexal mass that required
surgery, as judged by a clinician. The IOTA study group
collected data between 1999 and 2012. IOTA was established
to develop and validate diagnostic models for adnexal masses
based on large multicentre datasets using a standardised
ultrasound examination protocol, terms, and definitions.20-26
Patients were recruited from 24 centres in 10 countries. Twelve
centres were labelled oncology centres, that is, tertiary referral
centres with a specific gynaecology oncology unit. The
remaining centres included general hospitals and gynaecology
ultrasound units not linked to an oncology centre. Data collection
was carried out in phases: phase 1 between 1999 and 2002,
phase 1b between 2002 and 2005, phase 2 between 2005 and
2007, and phase 3 between 2009 and 2012.21-24
Patients
Patients referred to one of the participating centres for an
ultrasound examination because of a known or suspected adnexal
mass were eligible for inclusion. We included consecutive
patients with at least one adnexal mass judged not to be a
physiological cyst, who were examined with transvaginal
ultrasound by a principal investigator and later selected for
surgical intervention. The decision to operate was made by the
managing clinician on the basis of the full clinical picture,
including the ultrasound report, the latter being based on the
ultrasound examiner’s subjective assessment of the ultrasound
image. Following the requirements of the local ethics
committees, we obtained oral or written informed consent from
the women before their ultrasound scan and surgery. Exclusion
criteria were refusal for transvaginal ultrasonography, pregnancy
at the time of presentation, and surgical removal of the mass
more than 120 days after the ultrasound examination. If more
than one mass was detected, we used the mass with the most
complexmorphology on the ultrasound scan.Whenwe observed
masses with similar morphology, we used the largest or the one
most easily accessible by ultrasound.21-23
Data collection and reference standard
To collect clinical information we took a standardised history
from each patient. All patients underwent a standardised
transvaginal ultrasound examination.20 Transabdominal
sonography was added for women with large masses that could
not be visualised in full by a transvaginal probe. We collected
gray scale and Doppler ultrasound information in line with the
research protocols. More information can be found in previous
reports.21-23 Participating centres were encouraged to measure
serumCA-125.We used second generation immunoradiometric
assay kits for CA-125 II from Roche Diagnostics, Centocor,
Cis-Bio, Abbott Laboratories, Bayer Diagnostics, bioMérieux,
DiaSorin, Siemens, and Beckman Coulter. All kits used the
OC125 antibody.
The reference standard was the histopathological diagnosis of
the mass after surgical removal by laparotomy or laparoscopy
as considered appropriate by the surgeon, and the stage of
malignant tumours using the classification of the International
Federation of Gynecology and Obstetrics (FIGO).27 The excised
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tissues underwent histological examination at the local centre.
Histological classification was performed without knowledge
of the ultrasound results. The final diagnosis was divided into
five tumour types: benign, borderline, stage I invasive, stage
II-IV invasive, and secondary metastatic cancer.
Data were entered through dedicated and secure data collection
systems, web based for phase 1, and through a local study screen
(Astraia software, Munich, Germany) for later phases.21-23 To
ensure data integrity, several clinicians and statisticians used
built-in automatic checks and manual review and cleaning of
data.
Statistical analysis
We developed a prediction model using data from the women
included in IOTA phases 1, 1b, and 2 (n=3506) and validated
the model on data from the women included in phase 3
(n=2403).
The serum CA-125 tumour marker was not a mandatory
variable, andmeasurements were missing in 31% of the patients.
As described in detail in supplementary appendix A, we used
multiple imputation to deal with missing values for CA-125.28
We created 100 imputations, resulting in 100 completed datasets.
We selected variables in two stages (see supplementary appendix
B for details). Firstly, to avoid over-fitting we reduced the
number of potential predictors to 10 based on subject matter
knowledge29 30 and the stability of the predictors over centres.31
We selected four clinical variables—age (years), serumCA-125
level (U/mL), family history of ovarian cancer (yes/no), and
type of centre (oncology centre v other hospitals), and six
ultrasound variables—the maximum diameter of the lesion
(mm), proportion of solid tissue (that is, the maximum diameter
of the largest solid component divided by themaximum diameter
of the lesion), presence of more than 10 cyst locules (yes/no),
number of papillary projections (0, 1, 2, 3, >3), presence of
acoustic shadows (yes/no), and presence of ascites (yes/no).
Oncology centres were defined as tertiary referral centres with
a specific gynaecology oncology unit.We included the variable
“type of centre” because the risk of a malignant tumour is likely
to be higher in oncology centres than in other centres, even after
adjustment for the characteristics of patients and tumours.
Secondly, we carried out further data driven selection using a
method based on multivariable fractional polynomials.32 This
method simultaneously selects variables and determines the
optimal transformation of numerical variables using fractional
polynomials. We forced age and type of centre into the model
by default.
To acknowledge variability between centres we used
multinomial logistic regression with random centre intercepts
to construct the polytomousmodel.33Wemultiplied the predictor
coefficients with uniform “shrinkage factors” to avoid
exaggerated model coefficients (see supplementary appendix
C for details).30 34 We trained the model on each of the 100
completed datasets following multiple imputation. Probabilities
were derived by averaging linear predictors (without the random
effects) and odds ratios by averaging model coefficients.
We evaluated the model for discrimination and calibration
performance.35 To assess discrimination we first obtained the
area under the receiver operating characteristic curve (AUC)
for the basic discrimination between benign and malignant
tumours. We calculated sensitivity and specificity for the
cut-offs 3%, 5%, 10%, and 15% total risk of malignancy (that
is, the sum of the estimated risks of the four malignant subtypes).
We then also computed AUCs for each pair of tumour types
using the conditional risk method.36 For the five tumour types,
there are 10 pairwise AUCs. Finally, we calculated the
polytomous discrimination index, a polytomous version of the
AUC.37 This index estimates the average proportion of patients
who are correctly identified by the model when presented with
five patients, one with each tumour type. For five groups, the
polytomous discrimination index ranges between 0.20
(worthless) and 1 (perfect). A discrimination plot was used to
visualise discrimination performance.36
To assess calibration of the predicted probabilities we produced
calibration plots showing the relation between predicted and
observed probabilities for each type of tumour. The plots were
based on a parametric multinomial logistic recalibration
analysis,38 using random centre intercepts. We used the
probabilistic results of this analysis, including the random
effects, as observed probabilities, which were plotted against
the predicted probabilities.
Because model validation was successful, we updated the model
on the pooled data (n=5909) to make full use of all available
information. Predicted probabilities based on this model can
then be compared with baseline probabilities for each type of
tumour. The baseline probabilities were estimated through a
random intercepts multinomial logistic regression model
containing only intercept terms. All analyses were performed
with SAS 9.3 (SAS Institute, Cary, USA).
Results
In total, data on 6169 patients were recorded in the databases
for phases 1, 1b, 2, and 3. We excluded 255 patients (4.1%):
163 (2.6%) based on exclusion criteria (51 pregnant women,
112 women received surgery >120 days after the ultrasound
examination), 91 (1.5%) because of data errors or uncertain or
missing final histology, and one due to protocol violation. Based
on logistic regression influence diagnostics39 and further data
review of the archived datasets, we omitted five additional cases.
Thus data on 5909 women were used. Table 1⇓ gives an
overview of participating centres, included patients, and the
reference standard; supplementary table S1 the histological
diagnoses and FIGO stages; and supplementary table S2 the
personal and reproductive characteristics of the patients. The
observed rate of malignancy varied between 22% and 66% in
oncology centres and between 0% and 30% in other hospitals.
Model development, temporal validation, and
updating
We included nine variables in the Assessment of Different
NEoplasias in the adneXa (ADNEX)model: age, serumCA-125
level (log transformed), type of centre, maximum diameter of
the lesion (log transformed), proportion of solid tissue (with
quadratic term), number of papillary projections, more than 10
cyst locules, acoustic shadows, and ascites. Family history of
ovarian cancer was dropped by the variable selection analysis.
Table 2⇓ shows descriptive statistics for the 10 variables selected
a priori. The AUC of the ADNEX model for the basic
discrimination between benign and malignant tumours was
0.954 (95% confidence interval 0.947 to 0.961) on the
development data and 0.943 (0.934 to 0.952) on the validation
data (table 3⇓). The discrimination between benign and
malignant was consistent over centres (see supplementary figure
S1). Using a cut-off of 10% to predict malignancy, the sensitivity
was 96.5% and specificity 71.3% on the validation data (table
3). The validation AUCwas 0.85 for benign tumours compared
with borderline tumours, 0.92 for benign tumours compared
with stage I cancer, 0.99 for benign tumours compared with
stage II-IV cancer, and 0.95 for benign tumours compared with
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secondary metastatic cancer (table 4⇓). Validation AUCs
between malignant subtypes varied between 0.71 and 0.95. The
model showed fair discrimination between stage I cancer and
borderline tumours (validation AUC 0.75) and between stage I
cancer and secondary metastatic cancer (validation AUC 0.71).
It was well able to distinguish stage II-IV cancer from other
malignancies (AUCs for stage II-IV cancer versus borderline
tumours was 0.95, versus stage I cancer was 0.87, and versus
secondary metastatic cancer was 0.82). The polytomous
discrimination index was 0.56 (0.54 to 0.59) on the validation
data. Supplementary table S3 presents separate results for
oncology centres and other hospitals.
The calibration plots for all five tumour types showed acceptable
calibration of the estimated risks (fig 1⇓). High risks for
secondary metastatic cancer were overestimated, but such high
risks were uncommon. Calibration plots for oncology centres
and other hospitals were similar (see supplementary figures S2
and S3).
Tables 3 and 4 and supplementary table S3 show the
discrimination performance of the ADNEX model after it was
updated on the pooled data. The discrimination plot shows that
the predicted probability of a specific tumour type is highest
for patients with a matching reference standard (fig 2⇓)—for
example, patients with histologically confirmed borderline
tumours had the highest probabilities of a borderlinemalignancy.
TheADNEXmodel formula is given in supplementary appendix
D. The effects of the predictors are presented as odds ratios in
table 5⇓. Proportion of solid tissue and serumCA-125 level had
the strongest independent relations with the outcome, as judged
by the test statistic for the model coefficients (not shown). Type
of centre was the weakest predictor, indicating that most of the
differences in malignancy rates were captured by the other
predictors.
Deriving a similar model without CA-125 level as a predictor
mainly affected discrimination between stage II-IV cancer and
other malignancies (see supplementary table S4): validation
AUCs decreased from 0.82 to 0.59 (stage II-IV cancer v
metastatic cancer), from 0.87 to 0.76 (stage II-IV cancer v stage
I cancer), and from 0.95 to 0.91 (stage II-IV cancer v borderline
tumours).
Implementation of ADNEX and illustrative
example
The final ADNEX model is available online and in mobile
applications (www.iotagroup.org/adnexmodel/). The applications
allow risk calculation even without information on serum
CA-125 level, despite the decrease in performance. As an
example, we assess a 55 year old woman at a centre for
gynaecological oncology. Her serumCA-125 level is 42 U/mL.
Ultrasound examination reveals an adnexal mass with more
than 10 cyst locules, no papillary projections, no acoustic
shadows, ascites, a maximum lesion diameter of 120 mm, and
a maximum diameter of the largest solid component of 20 mm
(that is, proportion of solid tissue is 20/120). The ADNEXmodel
gives the following probabilities: 37.4% for borderline tumour,
10.8% for stage I cancer, 8.4% for stage II-IV cancer, and 11.0%
for secondary metastatic cancer. The total risk of malignancy
is 37.4+10.8+8.4+11.0=67.6%. The tumour is most likely to be
a borderline tumour as opposed to any other type of malignancy.
If the CA-125 level was unavailable, predicted probabilities
would be 25.2% (borderline), 8.3% (stage I), 35.8% (stage
II-IV), and 11.5% (metastatic). Baseline probabilities for each
type of tumour are 6.3% for borderline tumour, 7.5% for stage
I, 14.1% for stage II-IV, and 4.0% for metastatic cancer.
Discussion
We developed and temporally validated a prediction model that
is able to discriminate between five types of adnexal tumour
(benign, borderline, stage I cancer, stage II-IV cancer, and
secondary metastatic cancer), while still showing excellent
overall discriminative capacity between benign and all malignant
tumours. On the validation data, the previously proposed 10%
risk cut-off for the total risk of malignancy21 resulted in 96.5%
sensitivity and 71.3% specificity. The ADNEX model
discriminated well between benign tumours and each of four
types of malignancy (validation area under the receiver operating
characteristic curves (AUCs) between 0.85 and 0.99).Moreover,
the model was able to distinguish stage II-IV cancer from other
malignancies (validation AUCs between 0.82 and 0.95) and
showed fair discrimination between stage I cancer and borderline
tumours (AUC 0.75) and stage I cancer and secondarymetastatic
cancer (AUC 0.71). The model uses three clinical predictors
(age, serum CA-125 level, type of centre) and six ultrasound
predictors (maximal diameter of lesion, proportion of solid
tissue, more than 10 cyst locules, number of papillary
projections, acoustic shadows, and ascites). SerumCA-125 level
and proportion of solid tissue were the strongest predictors.
Results in relation to other studies
The polytomous approach to adnexal tumour diagnosis is novel.
We do not know of multivariable polytomous models in this
area outside the work of the International Ovarian Tumour
Analysis (IOTA) group.16 In a recent meta-analysis evaluating
the performance of prediction models and rules to characterise
adnexal pathology, approaches by IOTA such as the logistic
regression model LR221 and the simple rules25 26 (a set of 10
ultrasound features) performed best for the overall
discrimination between benign and all malignant masses.40 The
Royal College of Obstetricians and Gynaecologists has included
the simple rules in their guidelines on management of adnexal
tumours in premenopausal patients.41 The ADNEX model’s
performance is similar to, or even slightly better than, that of
LR2 and simple rules. For example, the AUC of LR2 on the
validation data (IOTA phase 3) was 0.92.42 In contrast with LR2
and simple rules, the ADNEX model also enables specific
subtyping of malignancy using risk estimates.
Strengths and weaknesses of this study
Our study has several strengths and limitations. Firstly, the
strengths of the present study are that we used a large number
of patients that were prospectively examined at 24 centres in
10 countries using a standardised protocol, avoided strong data
driven variable selection, and conducted a large temporal
validation of the model. After validation, we used the pooled
data from almost 6000 patients to update the model coefficients.
We would therefore expect our results to be generalisable.
Secondly, it may be seen as an advantage that a histological
diagnosis was obtained for every included tumour. This could
also be regarded as a limitation, because the model is based on
patients who were selected for surgery. Hence we cannot be
certain that the test performance of the ADNEX model would
be maintained if applied to a population of tumours, of which
some were selected for expectant management. However, this
argument holds for all prediction models for the diagnosis of
ovarian tumours. Thirdly, the centres used different assay kits
for CA-125 assessment. This can also be interpreted as both a
strength and a limitation: using different kits introduces
variability in CA-125 levels (although this variability is minor43),
reflects clinical reality, and yields results that are less dependent
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on assay. Fourthly, a potential limitation is that experienced
operators examined all tumours in the study. However, other
studies have shown that dichotomous models developed by the
IOTA group using ultrasound variables similar to those in the
current study, work well in the hands of non-expert level 244
ultrasound examiners.45 46 Fifthly, there was no central review
of pathology. In phase 1 of the IOTA study, 10% of the patients
were selected at random for central review of pathology.21
Because we found no clinically important differences in reported
outcomes between local and central reports, such centralised
review was not performed in later phases of the IOTA study.
This may nevertheless have introduced bias. For example,
distinguishing borderline tumours from benign tumours or stage
I cancer may be difficult for pathologists, and confusion of these
tumour types might have impacted on the ability of the ADNEX
model to correctly distinguish between them.
Implications for clinical practice
The ADNEXmodel has clear potential to optimise management
of women with an adnexal tumour. Currently the risk of
malignancy index (RMI)47 is often used to characterise adnexal
masses as benign or malignant. However, the index had much
poorer performance for discrimination between benign and
malignant tumours (AUC 0.88, 67.1% sensitivity, and 90.6%
specificity at the typical risk of malignancy index cut-off of
200) than the ADNEX model when tested on our validation
data.42 In addition to offering excellent discrimination between
benign and malignant tumours, the ADNEX model predicts
type of malignancy. Knowledge of the specific type of adnexal
pathology before surgery is highly likely to improve patient
triage, and it also makes it possible to optimise treatment. This
in turn may reduce morbidity and lead to enhanced survival
from different types of ovarian malignancy. The correct
identification of stage I cancer is particularly important.19 The
ADNEX model can discriminate well between stage I cancers
and benign tumours and between stage I cancers and advanced
stage cancer. In addition, the ADNEX model can discriminate
well between advanced primary cancer and secondarymetastatic
cancer. The latter result is largely achieved through the use of
serum CA-125 level as a predictor. Although CA-125 level has
little added value over ultrasound information when
distinguishing benign from malignant tumours,17 the present
study shows that serum CA-125 level is important for good
discrimination between stage II-IV cancer and stage I and
secondary metastatic cancer. An inconvenience that ADNEX
shares with well known models to predict ovarian malignancy,
such as the risk of malignancy index47 and the risk of ovarian
malignancy algorithm (ROMA),48 is that predictions can only
be made once the results of blood sample analyses are available.
ADNEX implementations also allow risk calculation without a
CA-125 level, but this will result in poorer discrimination
between stage II-IV cancers and other types of malignancy.
We expect that the performance of the ADNEX model will be
maintained in the hands of non-expert ultrasound examiners on
condition that the examiners are familiar with the IOTA terms
and definitions and use the IOTA examination andmeasurement
techniques (see the IOTA consensus statement20). How the
predicted risks from ADNEX should be used clinically must be
decided on an individual basis, because patient management
depends on many factors. When deciding on treatment of an
adnexal mass, the likelihood of a specific type of malignancy
is pivotal, but age, symptoms, wish to preserve fertility,
comorbidity, and operative risks are also important factors.
However, the ADNEX predictions may form a solid and
objective base for optimal management of patients and could
be incorporated in national and international clinical guidelines.
Key future research
Future work entails regular updating of ADNEX model
coefficients using newly collected data, andmonitoring of model
performance. In addition, studies including patients who are
managed conservatively are critically needed. This is the subject
of phase 5 of the IOTA study, for which data collection started
early in 2013. Finally, the ADNEX model could be optimised
for use as a second stage test if screening for ovarian cancer is
introduced into clinical practice.6
Conclusion
The ADNEX model has the potential to change management
decisions for womenwith an adnexal tumour. This could impact
considerably on the morbidity and mortality associated with
adnexal pathology.
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What is already known on this topic
Referring patients with ovarian cancer to specialised gynaecology oncology centres impacts positively on survival
Currently in Europe and the United States only a minority of women are triaged to receive specialist care in a gynaecology oncology
centre
Personalised management, including fertility sparing surgery, requires knowledge of the nature of an ovarian mass
Prediction models exist that can discriminate between benign and malignant ovarian tumours but they do not subclassify malignant
tumours
What this study adds
The ADNEX model discriminated well between benign and malignant ovarian tumours
The model was also able to discriminate between benign, borderline, stage I invasive, stage II-IV invasive, and secondary metastatic
tumours
The ADNEXmodel may improve patient triage and decisions about management, and so positively impact on the morbidity and mortality
associated with adnexal pathology
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Tables
Table 1| Number of patients in each centre, and type of centre
MetastaticStage II-IVStage IBorderlineBenign*TotalDatasetParticipating centres and data summaries
Oncology centres:
511714864596 (64)930D, VUniversity Hospitals Leuven, Belgium
742137944377 (48)787D, VUniversita Cattolica del Sacro Cuore, Rome,
Italy
6401730308 (77)401D, VOspedale San Gerardo, Monza, Italy
241333146120 (34)354D, VGeneral Faculty Hospital, Prague, Czech
Republic
191092721135 (43)311D, VIstituto Europeo di Oncologia, Milan, Italy
861258183 (64)285D, VMedical University Lublin, Poland
5311019148 (69)213VUniversity of Bologna, Italy†
82671267 (56)120VKarolinska University Hospital, Stockholm,
Sweden
51581378 (66)119DKing’s College Hospital, London, UK
3114257 (74)77D, VSkåne University Hospital Lund, Sweden
3120157 (78)73DChinese PLA General Hospital, Beijing,
People’s Republic of China
2610145 (70)64D, VUniversita degli Studi di Udine, Italy
24207 (47)15D, VIstituto Nazionale dei Tumori, Naples, Italy
Other hospitals:
18773835608 (78)776D, VSkåne University Hospital Malmö, Sweden
2281714367 (86)428D, VZiekenhuis Oost-Limburg, Genk, Belgium
81388224 (86)261D, VOspedale San Giovanni di Dio, Cagliari, Italy
31384195 (87)223D, VDCS Sacco University of Milan, Italy
2333124 (92)135DUniversity of Bologna, Italy†
3133282 (80)103D, VUniversita degli Studi di Napoli, Naples, Italy
052271 (89)80DHôpital Boucicaut, Paris, France
024157 (89)64DCentre Medical des Pyramides, Maurepas,
France
012826 (70)37VInstitut Universitari Dexeus, Barcelona, Spain
012117 (81)21DMacedonio Melloni Hospital, Italy
000021 (100)21VOspedale dei Bambini Vittore Buzzi, Milan,
Italy
001010 (91)11DSt Joseph’s Hospital, Hamilton, Canada
Data summaries:
210 (6)*832 (22)*268 (7)*261 (7)*2178 (58)3749D, VOncology centres only
36 (2)*156 (7)*88 (4)*78 (4)*1802 (83)2160D, VOther hospitals only
120 (3)*467 (13)*176 (5)*186 (5)*2557 (73)3506DDevelopment data only
126 (5)*521 (22)*180 (7)*153 (6)*1423 (59)2403VValidation data only
246 (4)*988 (17)*356 (6)*339 (6)*3980 (67)5909D, VTotal pooled dataset
D=contributed to development dataset; V=contributed to validation dataset.
*Number (percentage).
†Centre changed to an oncology referral centre after completion of IOTA phase 2 (that is, between patient recruitment for development and validation datasets).
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Table 2| Descriptive statistics of the a priori considered predictors by tumour type in pooled dataset (n=5909). Values are numbers
(percentages) unless stated otherwise
Metastatic (n=246)Stage II-IV (n=988)Stage I (n=356)Borderline (n=339)Benign (n=3980)Variables
57 (47-68)59 (50-67)54 (44-64)49 (36-62)42 (32-54)Median (interquartile range) age (years)
91 (29-271)442 (145-1238)51 (20-195)30 (16-86)18 (11-39)Median (interquartile range) serum CA-125 (U/mL)*
5 (2.0)57 (5.8)13 (3.7)10 (3.0)79 (2.0)Family history of ovarian cancer
86 (56-124)85 (56-123)106 (71-153)86 (51-150)63 (45-87)Median (interquartile range) maximal diameter of lesion (mm)
Solid tissue:
234 (95.1)968 (98.0)328 (92.1)267 (78.8)1322 (33.2)Presence of solid tissue
100 (64-100)100 (56-100)61 (38-100)37 (24-59)42 (20-100)Median (interquartile range) proportion solid tissue if present
(%)
No of papillary projections:
213 (86.6)772 (78.1)227 (63.8)135 (39.8)3424 (86.0)0
12 (4.9)56 (5.7)25 (7.0)69 (20.4)333 (8.4)1
0 (0)30 (3.0)17 (4.8)21 (6.2)80 (2.0)2
2 (0.8)28 (2.8)17 (4.8)24 (7.1)66 (1.7)3
19 (7.7)102 (10.3)70 (19.7)90 (26.5)77 (1.9)>3
36 (14.6)93 (9.4)69 (19.4)74 (21.8)199 (5.0)>10 cyst locules
10 (4.1)30 (3.0)18 (5.1)8 (2.4)676 (17.0)Acoustic shadows
90 (36.6)473 (47.9)65 (18.3)28 (8.3)64 (1.6)Ascites
62 (25.2)163 (16.5)71 (19.9)62 (18.3)1447 (36.4)Missing values for CA-125
*Results based on multiple imputation of missing values.
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Table 3| Diagnostic performance of ADNEX model when using different thresholds for total probability of malignancy (sum of probabilities
of four subtypes of ovarian malignancy)
After updating on pooled data (n=5909)Validation data (n=2403)Development data (n=3506)Threshold
for Diagnostic
odds ratio
SpecificitySensitivity
AUC
Diagnostic
odds ratio
SpecificitySensitivity
AUC
Diagnostic
odds ratio
SpecificitySensitivity
AUC
probability
of
malignancy*
———0.950
(0.944
to
0.955)
———0.943
(0.934
to
0.952)
———0.954
(0.947
to
0.961)
Not
applicable
86.243.4 (41.8
to 45.0)
99.1 (98.6
to 99.5)
—76.846.6 (44.0
to 49.2)
98.9 (98.0
to 99.4)
—93.652.3 (50.4
to 54.3)
98.8 (97.9
to 99.4)
—3%
78.061.1 (59.5
to 62.6)
98.0 (97.3
to 98.6)
—88.159.4 (56.8
to 62.0)
98.4 (97.4
to 99.1)
—87.965.4 (63.6
to 67.3)
97.9 (96.8
to 98.7)
—5%
72.773.2 (71.8
to 74.6)
96.4 (95.4
to 97.2)
—69.271.3 (68.9
to 73.7)
96.5 (95.2
to 97.6)
—72.075.5 (73.8
to 77.2)
95.9 (94.4
to 97.1)
—10%
63.478.7 (77.4
to 79.9)
94.5 (93.4
to 95.5)
—54.777.2 (74.9
to 79.3)
94.2 (92.5
to 95.6)
—71.981.0 (79.4
to 82.5)
94.4 (92.8
to 95.8)
—15%
AUC=area under receiver operating characteristic curve.
Exact binomial 95% confidence intervals are reported in parentheses.
*Probability equal to or more than threshold indicates malignancy.
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Table 4| Polytomous discrimination performance of ADNEXmodel on development data, validation data, and after updating on pooled data
After updating on pooled data (n=5909)Validation data (n=2403)Development data (n=3506)Performance measures
0.88 (0.87 to 0.90)0.85 (0.82 to 0.88)0.91 (0.88 to 0.93)AUC benign v borderline
0.93 (0.92 to 0.94)0.92 (0.90 to 0.93)0.94 (0.92 to 0.96)AUC benign v stage I
0.99 (0.98 to 0.99)0.99 (0.98 to 0.99)0.99 (0.98 to 0.99)AUC benign v stage II-IV
0.96 (0.95 to 0.97)0.95 (0.93 to 0.97)0.96 (0.95 to 0.98)AUC benign v metastatic
0.75 (0.71 to 0.79)0.75 (0.69 to 0.79)0.71 (0.65 to 0.76)AUC borderline v stage I
0.93 (0.91 to 0.95)0.95 (0.93 to 0.96)0.91 (0.88 to 0.93)AUC borderline v stage II-IV
0.88 (0.85 to 0.91)0.87 (0.82 to 0.91)0.86 (0.81 to 0.90)AUC borderline v metastatic
0.85 (0.82 to 0.87)0.87 (0.83 to 0.90)0.83 (0.79 to 0.86)AUC stage I v stage II-IV
0.75 (0.70 to 0.78)0.71 (0.65 to 0.76)0.77 (0.71 to 0.82)AUC stage I v metastatic
0.80 (0.76 to 0.83)0.82 (0.78 to 0.86)0.76 (0.71 to 0.81)AUC stage II-IV v metastatic
0.569 (0.553 to 0.586)0.567 (0.540 to 0.591)0.554 (0.530 to 0.579)Polytomous discrimination index
AUC=area under the receiver operating characteristic curve.
With five tumour types, the polytomous discrimination index for random prediction equals 0.2, hence its value cannot be directly compared with AUCs.
95% confidence intervals are shown in parentheses.
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Table 5| Odds ratios for predictors in ADNEX model after it was updated on pooled dataset (n=5909)
Metastatic v benignStage II-IV v benignStage I v benignBorderline v benignPredictor
1.40 (1.24 to 1.57)1.67 (1.50 to 1.86)1.19 (1.09 to 1.30)1.05 (0.96 to 1.14)Patient age, per 10 years
1.32 (1.19 to 1.46)2.15 (1.96 to 2.36)1.22 (1.12 to 1.32)1.12 (1.03 to 1.22)Serum CA-125, per doubling*
1.57 (1.23 to 1.99)1.54 (1.25 to 1.89)2.40 (1.97 to 2.91)1.45 (1.22 to 1.73)Maximal diameter of lesion, per
doubling *
Proportion solid tissue (%)†:
7.09 (4.01 to 12.5)16.9 (10.5 to 27.0)12.8 (8.62 to 18.9)5.44 (3.88 to 7.64)33 v 0 (no solid tissue)
4.25 (3.46 to 5.23)4.74 (3.92 to 5.73)3.49 (2.99 to 4.08)1.55 (1.32 to 1.81)67 v 33
2.55 (1.60 to 4.06)1.33 (0.92 to 1.94)0.95 (0.68 to 1.35)0.44 (0.29 to 0.67)100 v 67
2.46 (1.33 to 4.56)1.31 (0.74 to 2.32)2.21 (1.42 to 3.43)3.96 (2.65 to 5.90)>10 cyst locules
1.24 (1.01 to 1.52)1.48 (1.28 to 1.71)1.49 (1.33 to 1.68)1.83 (1.65 to 2.03)No of papillary projections
0.08 (0.04 to 0.18)0.09 (0.05 to 0.17)0.15 (0.09 to 0.26)0.13 (0.06 to 0.28)Acoustic shadows
5.14 (3.00 to 8.79)3.85 (2.39 to 6.20)1.57 (0.93 to 2.67)2.64 (1.44 to 4.86)Ascites
2.25 (1.04 to 4.87)1.58 (0.78 to 3.21)1.57 (0.89 to 2.78)2.59 (1.32 to 5.11)Oncology referral centre
*This variable is log transformed (log with base 2) such that the odds ratio represents the effect for each doubling of the value.
†This variable represents the maximal diameter of the largest solid component divided by the maximal diameter of the lesion (range 0% to 100%), with 0% indicating
that there is no solid tissue and 100% indicating that the maximal diameter of the largest solid component equals the maximal diameter of the lesion. The variable
has a quadratic effect in the model, hence we report odds ratios for 33% v 0%, 67% v 33%, and 100% v 67%.
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Figures
Fig 1 Calibration plots of predicted probabilities for each type of tumour. Data have been calculated using validation data
(n=2403). Plots show how well the predicted probabilities (x axis) agree with observed probabilities (y axis). For perfect
agreement, the calibration curve falls on the ideal diagonal line. Histograms below plots show distribution of predicted
probabilities
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g5920 doi: 10.1136/bmj.g5920 (Published 16 October 2014) Page 13 of 14
RESEARCH
Fig 2 Discrimination plot of ADNEX model after it was updated on pooled dataset (n=5909). For each predicted tumour
type, box plots of probabilities are presented for each confirmed tumour type (reference standard). Red vertical lines show
baseline probabilities for each type of tumour. For example, the baseline probability of a benign tumour is 0.681; for most
women with a benign tumour the predicted probability of a benign tumour was higher than 0.9, whereas most women with
an ovarian malignancy (most notably stage II-IV cancer) had clearly lower predicted probabilities of a benign tumour
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